drugset / Trial / NCT05785754
DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a multicenter, open-label, Phase 1 study to assess the effects of DCSZ11 as a monotherapy and in combination in patients with advanced or metastatic solid tumors. The study consists of an Escalation Phase (Phase 1a) and a Dose Expansion/Optimization Phase (Phase 1b).
Timeline
- Start
- 2023-06-28
- Primary completion
- 2026-12
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DCSZ11 | Monoclonal antibody | 20 mg/kg | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | — | — |
| Background | Doxorubicin | Other / unclassified | — | — |
| Background | Tebentafusp | Protein / enzyme biologic | — | — |
Indications
No indication recorded.